This Small-Cap Pharma Stock is Up 6 per cent! Lands Major Orders from 3 Countries!
A leading player in personal protection and healthcare products expands its international footprint
Cupid Limited has received new orders worth Rs 13.90 crore for its female condoms from Brazil, South Africa, and Angola. These orders will be fulfilled by Q1 FY26. The company sees female condoms as a high-value segment and expects continued growth in this category.
Leading Manufacturer in the Segment
Established in 1993, Cupid Limited is India’s leading manufacturer of male and female condoms, water-based lubricants, IVD kits, deodorants, perfumes, and personal care products. The company exports its products to over 105 countries and generates more than 90 per cent of its revenue from international markets.
Strong Production Capacity and Expansion Plans
Cupid has a manufacturing facility spread across 100,000 sq. ft. in Nashik, with an annual production capacity of 480 million male condoms, 52 million female condoms, 210 million lubricant jelly sachets, and 20 million IVD test kits. In March 2024, the company acquired land in Palava, Maharashtra, to increase its production capacity by 1.5 times. By FY26, the capacity will rise to 1.25 billion male condoms and 125 million female condoms annually.
WHO/UNFPA Certification and Global Presence
Cupid is the first company in the world to receive WHO/UNFPA prequalification for both male and female condoms. The company has a long-term agreement with WHO/UNFPA, further strengthening its global presence.
Stock Valuation and Performance
Cupid Limited has a market capitalization of Rs 1,972 crore and trades at a P/E ratio of 38.7, slightly higher than the industry average of 36.4. The company has a return on capital employed (ROCE) of 21.7 per cent and a return on equity (ROE) of 16.5 per cent. With a low debt-to-equity ratio of 0.05, the stock has shown strong momentum, closing at Rs 73.32 on February 13, up 6.06 per cent for the day.
Disclaimer: This article is for informational purposes only and not an investment advice.